MedWatch

Zealand Pharma will have crucial data ready in few weeks

The company is currently waiting on phase III data for glepaglutide, which could open many doors for the company in the future.

Photo: Zealand Pharma

Zealand Pharma has concluded a phase III study of drug candidate glepaglutide, and is now waiting on important data to come in before sharing it with the public, reports Danish media Finans.

Glepaglutide is Zealand’s attempt at treating the rare disease known as short bowel syndrome. The current market for this condition is dominated by the Gattex therapy sold by Takeda.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs